Navigation Links
Insmed to Present at 31st Annual J.P. Morgan Healthcare Conference
Date:12/13/2012

MONMOUTH JUNCTION, N.J., Dec. 13, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing and commercializing novel, targeted inhaled therapies for patients with high unmet need who are battling serious orphan lung diseases, today announced that the Company will be participating in the 31st Annual J.P. Morgan Healthcare Conference from January 7-10, 2013 at the Westin St. Francis Hotel in San Francisco.  Will Lewis, Insmed's President and CEO, will present a corporate overview on Thursday, January 10th at 1:30 p.m. Pacific time (4:30 p.m. Eastern time). 

A live audio webcast of Mr. Lewis' presentation will be made available in the Investor section of Insmed's website, http://www.insmed.com where it will be archived for 90 days.

Insmed management will be available for one-on-one meetings with investors and analysts throughout the conference from January 7-10, 2013.  To schedule an appointment, contact Anne Marie Fields of LHA at 212-838-3777 or afields@lhai.com or contact your J.P. Morgan representative.

About Insmed

Insmed Incorporated is a biopharmaceutical company dedicated to improving the lives of patients battling serious orphan lung diseases through the development and commercialization of novel, targeted inhalation therapies in orphan patient populations with critical unmet needs. Insmed's lead candidate, ARIKACE®, is engineered to deliver a proven and potent anti-infective directly to the site of serious lung infections to improve the efficacy, safety and convenience of treatment for at least two identified patient populations: cystic fibrosis (CF) patients with Pseudomonas aeuruginosa lung infections and patients with nontuberculous mycobacteria lung infections (NTM). Following positive phase 2 results in CF patients, Insmed's phase 3 registrational study of ARIKACE (CLEAR-108) in Europe and Canada has completed enrollment, and the Company expects top-line clinical results in mid-2013.  Insmed's U.S. phase 2 clinical trial in NTM (TARGET-NTM) is well under way with clinical results expected in late 2013.  The Company is currently preparing for regulatory filings and for commercialization, if and when regulatory approvals are obtained. For more information, please visit http://www.insmed.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Words, and variations of words, such as "intend", "expect", "will", "anticipate", "believe", "continue", "propose" and similar expressions are intended to identify forward-looking statements. Investors are cautioned that such statements in this release, including statements relating to the status, results and timing of results of pre-clinical studies and clinical trials and pre-clinical and clinical data and the anticipated benefits of Insmed's products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, without limitation, failure or delay of U.S. Food and Drug Administration and other regulatory reviews and approvals, competitive developments affecting our product development, delays in product development or clinical trials, patent disputes involving currently developing products, unexpected regulatory actions, delays or requests, the failure of future clinical trials, inability to successfully develop our product candidates or receive necessary regulatory approvals, inability to make product candidates commercially successful, changes in anticipated expenses, and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2011 and our Quarterly Report on Form 10-Q for the quarter ended September 30, 2012. Investors are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. We undertake no obligation to update these forward-looking statements to reflect events or circumstances or changes in our expectations.

Investor Relations Contact:
LHA
Anne Marie Fields
Senior Vice President
212-838-3777
afields@lhai.com

Bruce Voss
Managing Director
310-691-7100
bvoss@lhai.com


'/>"/>
SOURCE Insmed Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Insmed Incorporated Provides Corporate Update
2. Insmed Secures $20 Million Loan Agreement With Hercules Technology Growth Capital
3. Insmed Announces Financial Results For Second Quarter And Six-months Ended June 30, 2012
4. Insmed to Present at Stifel Nicolaus 2012 Healthcare Conference
5. Insmed Appoints 15-Year Life Sciences Industry Veteran Andrew Drechsler as Chief Financial Officer
6. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
7. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
8. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
9. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
10. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
11. Masimo to Present at 23rd Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 08, 2016 , ... Net-Translators, an industry-leading provider of ... its revamped and improved website. In an on-going effort to further educate customers ... better communicate how the company designs and delivers thorough, high-quality results for its ...
(Date:2/9/2016)... ... February 09, 2016 , ... The American Academy of Thermology ... offering its 2016 AAT Member Certification Qualification Course for Technicians via a two part ... which will include a detailed review of hardware, software, and camera setup/operations, aligns with ...
(Date:2/9/2016)... , Feb. 9, 2016  DNAtrix, a ... for cancer, announced that its lead product, ... Commission as an orphan medicinal product for ... form of glioma, strikes approximately 25,000 people ... http://photos.prnewswire.com/prnh/20160208/330986LOGO --> ...
(Date:2/9/2016)... 2016 Three-Year Initiative Supports Next Generation ... Part in Life-Changing Camp Experiences ... positively affect the lives of children born with rare diseases, as ... SHPG ) is announcing a new initiative designed to positively affect ... the future of rare disease care. --> To mark ...
Breaking Biology Technology:
(Date:2/1/2016)... -- Today, the first day of American Heart Month, the ... first of its kind workplace health solution that leverages ... first application of Watson to ... Welltok will create a new offering that combines AHA,s ... on Welltok,s health optimization platform. The effort is intended ...
(Date:1/27/2016)... 2016  Rite Track, Inc. a leading semiconductor equipment ... Chester, Ohio announced today the acquisition of PLUS ... in Austin, Texas , will significantly ... modifications, installations and technical support offerings for TEL Track ... commented, "PLUS has provided world class service including refurbishment, ...
(Date:1/22/2016)... 22, 2016 ... of the  "Global Behavioral Biometric Market ... --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced ... Biometric Market 2016-2020"  report to their ... Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced the ...
Breaking Biology News(10 mins):